Endo's management team has done a masterful job of cutting costs and maintaining an acceptable level of operating margins.
Endo pharma earnings free#
I would have expected a free fall in revenue to lead to huge operating losses.
If Endo can accelerate the new drugs it brings to market then it could help offset the slide in North America. The diminution in generics prices in North America could be intractable for now. Generics fell 37%, while new drug launches were down 67%. Large clients are demanding price cuts while the FDA is accelerating drug approval which is increasing competition. However, the North America Generics market is currently in a state of disarray. One would suspect that Generics (64% of total revenue) could potentially buoy the company until the Branded segment gets sorted out. The other problem is that Endo does not seem to have a moat. We should learn more from management this quarter whether the free fall in Branded segment has run its course. Last year, the FDA asked Endo to remove the opioid Opana from the market due to its public health consequences of abuse. Opioid prescriptions were 219 million in 2011 - nearly triple the number reported 20 years earlier despite the fact the level of pain felt by Americans may not have increased proportionately.
The Branded segment houses Endo's pain-related drugs like Opana, Percocet, Voltaren and Lidoderm. The company's association with opioid sales is well-known. The biggest decline came from Generics (down 43%) the Branded segment experienced a 21% decline, while International was off 41%. Both have hurt Endo's top line, which is in free fall.Įndo's Q4 2017 revenue fell 38% Y/Y. The FDA and lawmakers have made concerted efforts to help tamp down rising drug prices as well as runaway opioid prescriptions. The company has gotten lumped in with price-gougers like Valeant ( VRX) and Turing Pharmaceuticals who acquire brands and raise prices post-deal.
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/OVDZMWWEUVEMDOWX6O2KTMS2TQ.jpg "endo pharma earnings")
There is a war being fought over rising drug prices and Endo Pharmaceuticals ( ENDP) is in the middle of it. Investors should focus on the following key items: Diminution In Generics The revenue estimate implies a 30% decline Y/Y. Analysts expect revenue of $691.83 million and eps of $0.55.
Endo pharma earnings full#
The majority of its revenue comes from the United States.Ĭlick Here to get the full Stock Report for Endo International PLC stock.Endo Pharmaceuticals ( ENDP) reports quarterly earnings May 8th. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. ENDP earned $0.29 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 14.88.Įndo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. Over the past year the S&P 500 is up 34.96% while ENDP is lower by -23.06%. ENDP is lower by -$0.45 from the previous closing price of $4.72 on volume of 1,195,447 shares. Įndo International PLC (ENDP) stock has fallen -9.47% while the S&P 500 has risen 0.52% as of 9:59 AM on Tuesday, Oct 26. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.Īvailable options can also represent current sentiments for a given stock. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. Recent trends are a good indicator of current market sentiments. There is no information about the health of profitability of the underlying company in our sentiment score.Īs a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is a very short-term indicator that is entirely technical. See Full ENDP Report What is Stock Sentiment?
0 kommentar(er)
